Carbamazepine (CBZ) Industry Forecast 2017-2022 Global Carbamazepine (CBZ) Market Outlook 2017-202 | Page 2

Global Carbamazepine (CBZ) Market Outlook 2017
Carbamazepine (CBZ), sold under the tradename Tegretol among others, is a medication used primarily in the treatment of
epilepsy and neuropathic pain. For seizures it works as well as phenytoin and valproate. It is not effective for absence
seizures or myoclonic seizures. It may be used in schizophrenia along with other medications and as a second line agent in
bipolar disorder.
This report provides detailed analysis of worldwide markets for Carbamazepine (CBZ) from 2011-2016, and provides
extensive market forecasts (2016-2021) by region/country and subsectors. It covers the volumes, prices, historical growth
and future perspectives in the Carbamazepine (CBZ) market and further lays out an analysis of the factors influencing the
supply/demand for Carbamazepine (CBZ), and the opportunities/challenges faced by industry participants. It also acts as an
essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the
opportunities and develop business strategies.
The report has been prepared based on the synthesis, analysis, and interpretation of information about the global
Carbamazepine (CBZ) market collected from specialized sources. The report covers key technological developments in the
recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section
of the report provides a clear insight into the market share analysis of key industry players. The major players in the global
Carbamazepine (CBZ) market are TEVA (Israel), TARO (Israel), Jubilant Pharma (India), Zhejiang Jiuzhou (China), Jinan Jinda
(China), Sihuan Shengwu (China), Jiangsu Tohope (China), Shanghai Modern Hasen (China) etc.
Inquire for discount on this research report at
http://www.reportsnreports.com/contacts/discount.aspx?name=954057